CoChat

A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.

McWilliams, Robert R., Ko, Andrew H., Chiorean, E. Gabriela, Kwak, Eunice Lee, Lenz, Heinz-Josef, Nadler, Paul I., Wood, Debra L, Fujimori, Masamoto, Morita, Kohei, Inada, Tetsuhi, Kouji, Hiroyuki · 2015 · Journal of Clinical Oncology
Cited by 44

The DOI matches its Crossref record.

Abstract

e15270 Background: PRI-724 is a first-in-class cAMP-response element-binding protein (CBP)/β-catenin modulator that induces stem cell differentiation. In pre-clinical models, PRI-724 increases p300/β-catenin binding and promotes differentiation, eliminating tumor initiating cells and increasing sensitivity to cytotoxic drugs. Methods: Patients with APC who progressed following first-line therapy with FFX or FX were enrolled. A 3+3 dose escalation design was applied, with GEM (1000 mg/m2 of d1,8,15, 28 d cycle), and PRI-724 administered as a continuous infusion X 7 d every other week. The starting dose was decided at 320 mg/m2/d based on a prior Phase 1a PRI-724 monotherapy study. DLT is defined based on study treatment related AEs. PK and PD sampling for potential biomarkers of PRI-724 activity was performed. Results: The dose-escalation phase was completed with 10 patients in 3 cohorts (320, 640 and 905 mg/m2). Median age was 61 yrs(range 51-70). Nine of 10 pts (90 %) were evaluable for tolerability; 1 pt discontinued early for PD without DLT. Evaluable patients completed a median of 3 cycles (range 1 to 7). The maximum dose was determined to be 905 mg/m2/day, consistent with the Phase 1a study, with no observed DLTs and no MTD established. Of 153 reported AEs with 9 evaluable pts, five gr 3/4 AEs (1 abd pain, 3 neutropenia, and 1alk phos elev) were judged possibly related to study treatment. No related fatal events observed. Median PFS was 2.7 mo. [range 0.97 to 7.2]. Four had a decrease in CA19-9 at the end of Cycle2, with a median decrease of 43% [range 21-76%].Best response by RECIST: 6 SD (including 2 minor responses), 3 PD. Assessments of candidate biomarkers (MMP7 and Claudin 18) are ongoing. Conclusions: In this phase Ib study,PRI-724 administered in combination with GEM demonstrates acceptable toxicity in patients with APC after progression on FFX or FX, with some evidence of clinical activity. Biomarker studies in progress. This dose escalation study determined 905mg/m2/d was generally well tolerated with no MTD reached. A dose expansion cohort of additional 9 patients is enrolling. Clinical trial information: NCT01764477.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.33.15_suppl.e15270

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 44

Metadata

Authors
McWilliams, R. R., Ko, A. H., Chiorean, E. G., Kwak, E. L., Lenz, H.-J., Nadler, P. I., Wood, D. L., Fujimori, M., Morita, K., Inada, T., & Kouji, H.
Venue
Journal of Clinical Oncology
Published
2015-05-20
Volume
33
Issue
15_suppl
Pages
e15270-e15270
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2467186682
Cited by
44
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.e15270
The paper
McWilliams, R. R., Ko, A. H., Chiorean, E. G., Kwak, E. L., Lenz, H.-J., Nadler, P. I., Wood, D. L., Fujimori, M., Morita, K., Inada, T., & Kouji, H. (2015). A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.e15270

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.